Which has higher earnings and valuation, VOR or GRFS?

Grifols has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Grifols $8.51B 0.58 $454.82M $0.19 37.89

Does the media refer more to VOR or GRFS?

In the previous week, Vor Biopharma had 4 more articles in the media than Grifols. MarketBeat recorded 8 mentions for Vor Biopharma and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat Vor Biopharma's score of 0.02 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, EWTX or VOR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is EWTX or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Vor Biopharma N/A N/A N/A

Does the media favor EWTX or VOR?

In the previous week, Edgewise Therapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 8 mentions for Vor Biopharma. Edgewise Therapeutics' average media sentiment score of 0.52 beat Vor Biopharma's score of 0.02 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, VOR or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A ACADIA Pharmaceuticals $1.07B 4.09 $391M $2.22 11.45

Does the media refer more to VOR or ACAD?

In the previous week, Vor Biopharma had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 8 mentions for Vor Biopharma and 6 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.69 beat Vor Biopharma's score of 0.02 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, VOR or IOVA?

Vor Biopharma has higher earnings, but lower revenue than Iovance Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Iovance Biotherapeutics $263.50M 17.52 -$390.98M -$0.73 N/A

Does the media favor VOR or IOVA?

In the previous week, Iovance Biotherapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 13 mentions for Iovance Biotherapeutics and 8 mentions for Vor Biopharma. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Vor Biopharma's score of 0.02 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, TLX or VOR?

Vor Biopharma has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $890.79M 4.30 -$7.12M N/A N/A Vor Biopharma N/A N/A N/A N/A N/A

Is TLX or VOR more profitable?

Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Vor Biopharma N/A N/A N/A

Does the media prefer TLX or VOR?

In the previous week, Telix Pharmaceuticals had 21 more articles in the media than Vor Biopharma. MarketBeat recorded 29 mentions for Telix Pharmaceuticals and 8 mentions for Vor Biopharma. Telix Pharmaceuticals' average media sentiment score of 0.31 beat Vor Biopharma's score of 0.02 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 5 Very Positive mention(s) 11 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Vor Biopharma (VOR) Competitors

$19.37 -2.63 (-11.95%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$19.25 -0.12 (-0.62%)

As of 09:18 AM Eastern

Compare

VOR vs. GRFS, EWTX, ACAD, IOVA, and TLX

Should you buy Vor Biopharma stock or one of its competitors? Vor Biopharma's main competitors and comparable companies include Grifols (GRFS), Edgewise Therapeutics (EWTX), ACADIA Pharmaceuticals (ACAD), Iovance Biotherapeutics (IOVA), and Telix Pharmaceuticals (TLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vor Biopharma compare to Grifols?

Vor Biopharma (NASDAQ:VOR) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

97.3% of Vor Biopharma shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vor Biopharma had 4 more articles in the media than Grifols. MarketBeat recorded 8 mentions for Vor Biopharma and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat Vor Biopharma's score of 0.02 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma currently has a consensus price target of $41.71, suggesting a potential upside of 115.36%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 38.89%. Given Vor Biopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vor Biopharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Vor Biopharma has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Grifols has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Grifols has a net margin of 5.54% compared to Vor Biopharma's net margin of 0.00%. Grifols' return on equity of 6.21% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Grifols	5.54%	6.21%	2.39%

Grifols has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Grifols	$8.51B	0.58	$454.82M	$0.19	37.89

Summary

Vor Biopharma beats Grifols on 8 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Vor Biopharma (NASDAQ:VOR) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

97.3% of Vor Biopharma shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Edgewise Therapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 13 mentions for Edgewise Therapeutics and 8 mentions for Vor Biopharma. Edgewise Therapeutics' average media sentiment score of 0.52 beat Vor Biopharma's score of 0.02 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vor Biopharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Vor Biopharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Edgewise Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

Edgewise Therapeutics currently has a consensus price target of $51.33, suggesting a potential upside of 25.05%. Vor Biopharma has a consensus price target of $41.71, suggesting a potential upside of 115.36%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Vor Biopharma beats Edgewise Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Vor Biopharma compare to ACADIA Pharmaceuticals?

Vor Biopharma (NASDAQ:VOR) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Vor Biopharma had 2 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 8 mentions for Vor Biopharma and 6 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.69 beat Vor Biopharma's score of 0.02 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
ACADIA Pharmaceuticals	$1.07B	4.09	$391M	$2.22	11.45

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Vor Biopharma's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Vor Biopharma presently has a consensus target price of $41.71, indicating a potential upside of 115.36%. ACADIA Pharmaceuticals has a consensus target price of $34.36, indicating a potential upside of 35.12%. Given Vor Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Vor Biopharma is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

ACADIA Pharmaceuticals beats Vor Biopharma on 7 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Iovance Biotherapeutics?

Vor Biopharma (NASDAQ:VOR) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Vor Biopharma has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 13 mentions for Iovance Biotherapeutics and 8 mentions for Vor Biopharma. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Vor Biopharma's score of 0.02 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma presently has a consensus price target of $41.71, indicating a potential upside of 115.36%. Iovance Biotherapeutics has a consensus price target of $10.56, indicating a potential upside of 3.59%. Given Vor Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Vor Biopharma is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vor Biopharma has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Vor Biopharma's return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Vor Biopharma has higher earnings, but lower revenue than Iovance Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Iovance Biotherapeutics	$263.50M	17.52	-$390.98M	-$0.73	N/A

Summary

Vor Biopharma beats Iovance Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does Vor Biopharma compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Vor Biopharma (NASDAQ:VOR) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Vor Biopharma	N/A	N/A	N/A

Telix Pharmaceuticals presently has a consensus price target of $20.50, suggesting a potential upside of 81.90%. Vor Biopharma has a consensus price target of $41.71, suggesting a potential upside of 115.36%. Given Vor Biopharma's higher probable upside, analysts clearly believe Vor Biopharma is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.90

97.3% of Vor Biopharma shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Vor Biopharma has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$890.79M	4.30	-$7.12M	N/A	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Telix Pharmaceuticals had 21 more articles in the media than Vor Biopharma. MarketBeat recorded 29 mentions for Telix Pharmaceuticals and 8 mentions for Vor Biopharma. Telix Pharmaceuticals' average media sentiment score of 0.31 beat Vor Biopharma's score of 0.02 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	5 Very Positive mention(s)	11 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

Summary

Vor Biopharma beats Telix Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.30B	$3.98B	$7.31B	$13.28B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	N/A	13.88	274.10	25.70
Price / Sales	N/A	1,437.48	672.61	90.85
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	N/A	15.45	10.48	6.32
Net Income	N/A	-$22.82M	$3.49B	$359.73M
7 Day Performance	-11.51%	-1.68%	-0.68%	0.17%
1 Month Performance	-14.71%	-6.15%	-3.18%	-3.27%
1 Year Performance	-44.16%	30.67%	15.13%	5.58%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	1.7224 of 5 stars	$19.37 -12.0%	$41.71 +115.4%	-38.1%	$1.30B	N/A	N/A	76	News Coverage High Trading Volume
GRFS Grifols	4.8356 of 5 stars	$7.31 -1.2%	$10.00 +36.8%	-26.9%	$4.98B	$8.51B	38.47	25,247	News Coverage
EWTX Edgewise Therapeutics	3.3958 of 5 stars	$45.32 -3.5%	$50.33 +11.1%	+172.0%	$4.92B	N/A	N/A	127	Analyst Forecast
ACAD ACADIA Pharmaceuticals	4.5144 of 5 stars	$27.29 -0.6%	$34.36 +25.9%	+7.8%	$4.70B	$1.07B	12.29	798	Positive News Analyst Forecast High Trading Volume
IOVA Iovance Biotherapeutics	1.712 of 5 stars	$10.25 +2.3%	$9.11 -11.1%	+392.3%	$4.64B	$263.50M	N/A	975	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. GRFS, EWTX, ACAD, IOVA, and TLX

How does Vor Biopharma compare to Grifols?

Summary

How does Vor Biopharma compare to Edgewise Therapeutics?

Summary

How does Vor Biopharma compare to ACADIA Pharmaceuticals?

Summary

How does Vor Biopharma compare to Iovance Biotherapeutics?

Summary

How does Vor Biopharma compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. GRFS, EWTX, ACAD, IOVA, and TLX

How does Vor Biopharma compare to Grifols?

Do insiders and institutionals hold more shares of VOR or GRFS?

Does the media refer more to VOR or GRFS?

Do analysts recommend VOR or GRFS?

Which has more risk & volatility, VOR or GRFS?

Is VOR or GRFS more profitable?

Which has higher earnings and valuation, VOR or GRFS?

Summary

How does Vor Biopharma compare to Edgewise Therapeutics?

Do insiders & institutionals hold more shares of EWTX or VOR?

Does the media favor EWTX or VOR?

Is EWTX or VOR more profitable?

Which has better valuation and earnings, EWTX or VOR?

Which has more volatility & risk, EWTX or VOR?

Do analysts recommend EWTX or VOR?

Summary

How does Vor Biopharma compare to ACADIA Pharmaceuticals?

Does the media refer more to VOR or ACAD?

Which has more volatility & risk, VOR or ACAD?

Which has stronger valuation & earnings, VOR or ACAD?

Do insiders and institutionals have more ownership in VOR or ACAD?

Is VOR or ACAD more profitable?

Do analysts rate VOR or ACAD?

Summary

How does Vor Biopharma compare to Iovance Biotherapeutics?

Which has more volatility & risk, VOR or IOVA?

Does the media favor VOR or IOVA?

Do analysts prefer VOR or IOVA?

Do insiders & institutionals believe in VOR or IOVA?

Is VOR or IOVA more profitable?

Which has stronger earnings & valuation, VOR or IOVA?

Summary

How does Vor Biopharma compare to Telix Pharmaceuticals?

Is TLX or VOR more profitable?

Do analysts prefer TLX or VOR?

Do insiders and institutionals believe in TLX or VOR?

Which has preferable earnings & valuation, TLX or VOR?

Does the media prefer TLX or VOR?

Which has more risk and volatility, TLX or VOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools